HIV Conferences: Expert Coverage of Breaking Research: Recent Episodes
The Body PRO
The Body PRO's podcast conference coverage features a diverse collection of interviews with top HIV researchers and clinicians. Largely conducted on-site at the most important HIV conferences, including the Conference on Retroviruses and Opportunistic Infections and the Interscience Conference on Antimicrobial Agents and Chemotherapy, as well as meetings of the International AIDS Society and the Infectious Diseases Society of America, these interviews feature summaries and analyses of key research on a wide range of HIV-related issues, including antiretrovirals in development, HIV treatment strategies, complications of HIV and HAART, HIV coinfections, epidemiology, HIV prevention and quality of life. Many of these podcasts are accompanied by full interview transcripts and slides at TheBodyPRO.com.
Eric Daar, M.D., discusses emerging data from recently approved agents or agents available in expanded access.
Erna Kojic, M.D., discusses her research on the prevalence of cervical and anal HPV infection in HIV-infected women.
Michael Mugavero, M.D., discusses his study on how often patients at an HIV clinic in Birmingham miss their visits and why 40% of those patients missed a quarter or more of their appointments.
Chia-Ching Wang, M.D., discusses her study of menopausal and perimenopausal women, which looked at their mammograms and Pap smear results, cardiovascular risk factors and rates of osteoporosis, osteopenia and cardiovascular disease.
Christos Karatzios, M.D., discusses his study on the medical needs and social characteristics of adolescents infected with HIV early in life.
Turner Overton, M.D., discusses his research on whether women who start taking antiretrovirals to reduce the risk of perinatal transmission should continue antiretroviral therapy.
Jay Lalezari, M.D., discusses the BOSS study, the first randomized study to examine the use of a needle-free device for administration of Fuzeon (enfuvirtide, T-20).
Joseph Eron, M.D., discusses 48-week results of a study of raltegravir (MK-0518) in highly treatment-experienced patients.
Joseph J. Eron, M.D., reviews highlights of ICAAC, including 48-week data on maraviroc, a head-to-head comparison of darunavir + ritonavir to lopinavir/ritonavir in treatment-naive patients, and the results of a study using interleukin-2 to delay HAART initiation.
Pablo Tebas, M.D., discusses why people who stop taking HIV meds are potentially at a greater risk for cardiovascular disease than if they remain on treatment.
Ben Young, M.D., Ph.D., reviews his presentation, which analyzes the impact of Viread (tenofovir) on the kidney function of people who already have kidney disease.
Trevor Hawkins, M.D., provides an update on his view of the most important studies presented at ICAAC, including data presented on CCR5 inhibitors, and the ARTEMIS trial, in which darunavir (TMC114, Prezista) + ritonavir (RTV, Norvir) compared favorably to lopinavir/ritonavir (LPV/r, Kaletra) in treatment-naive patients.
Michael Silverman, M.D., discusses his poster on the declining prevalence of HIV in pregnant women in Zimbabwe -- a 41% drop that may be due to the country's declining economy.
Tristan Ferry, M.D., discusses his poster on incidence and risk factors for non-AIDS-defining, non-HAART-related severe clinical events.
Matthew Goetz, M.D. discusses his research on the impact of co-receptor tropism on disease progression in treatment-naive patients.
Prakash Sista, Ph.D. discusses how the presence of protease inhibitor mutation I50L is associated with HIV drug resistance to atazanavir (ATV, Reyataz) and increased susceptibility to other protease inhibitors in a variety of protease mutational backgrounds.
Roy Gulick, M.D., M.P.H., discusses the results of his two-year study on treatment-experienced patients taking vicriviroc (SCH 417690, SCH-D), a CCR5 inhibitor in development.
Joel Gallant, M.D., M.P.H., wraps up our daily recap series from the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention with a wide-ranging discussion of important studies on first-line therapy, therapy options for treatment-experienced patients, antiretrovirals in development, abacavir hypersensitivity testing and the metabolic impact of antiretroviral switching.
Eric Daar, M.D., discusses what he considers to be the two big studies of IAS 2007, the ongoing debate about when-to-start treatment, and his own take on circumcision as prevention in the developed world.
Pietro Vernazza, M.D., offers his take on the when-to-start HIV treatment debate, circumcision and cardiovascular complications.
Edwin DeJesus, M.D., F.A.C.P., discusses data supporting the possibility that at least some cross-resistance occurs between the integrase inhibitors in development: elvitegravir (GS 9137) and raltegravir (MK-0518).
Benoit Marin discusses the association between CD4+ count and viral load and death due to non-AIDS causes.
Annette Sohn, M.D., summarizes her plenary presentation on pediatric treatment issues and answers questions about global pediatric HIV.
Jonathan Uy, M.D., discusses how the initiation of HAART at a CD4+ cell count of 350 cells/mm3 is associated with a lower prevalence of antiretroviral resistance mutations at virologic failure.
Pietro Vernazza, M.D., discusses his poster on pre-exposure prophylaxis and timed unprotected intercourse for HIV-discordant heterosexual couples wanting to conceive a child.
Daniel Berger, M.D., discusses thought-provoking research on recently approved antiretrovirals and drugs in development, including darunavir, MK-0518 (raltegravir), TMC278 (rilpivirine) and CCR5 inhibitors.
Trevor Hawkins, M.D., discusses the TITAN study, reviewing the relative side effects profiles of darunavir (TMC114, Prezista) + ritonavir (Norvir) and lopinavir/ritonavir (Kaletra), and the study's implications on clinical practice.
Daniel Berger, M.D., recaps early research highlights from the conference, from HIV/hepatitis C coinfection to orally bioavailable fusion inhibitors in development.
Steven G. Deeks, M.D., discussed SMART substudy results and weighed in on the when-to-start HIV treatment debate.
Anthony Mills, M.D., discusses the results of the DUET-1 trial, a double-blind, placebo-controlled, phase 3 trial designed to assess the efficacy and safety of TMC125 (etravirine) in treatment-experienced patients with NNRTI and PI resistance.
Nancy Padian, Ph.D., summarizes her plenary presentation on prevention technologies such as microbicides, dental dams and the female condom. Dr. Padian then answers questions on her presentation.
Suraiya Rasheed, Ph.D., describes her research, which has shown that HIV infection of CD4+ cells enhances production of proteins associated with cardiovascular and other metabolic disorders.
Daniel J. Skiest, M.D., discusses ACTG 5170 quality of life results showing that patients who had a high CD4+ cell count before a treatment interruption saw their medication-related symptoms improve during the treatment interruption.